The Role of Microglia in the (Mal)adaptive Response to Traumatic Experience in an Animal Model of PTSD.
animal models
chemokine
immune system
microglia
post-traumatic stress disorder (PTSD)
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
28 Jun 2022
28 Jun 2022
Historique:
received:
12
05
2022
revised:
22
06
2022
accepted:
23
06
2022
entrez:
9
7
2022
pubmed:
10
7
2022
medline:
14
7
2022
Statut:
epublish
Résumé
The present study investigates whether predator scent-stress (PSS) shifts the microglia from a quiescent to a chronically activated state and whether morphological alterations in microglial activation differ between individuals displaying resilient vs. vulnerable phenotypes. In addition, we examined the role that GC receptors play during PSS exposure in the impairment of microglial activation and thus in behavioral response. Adult male Sprague Dawley rats were exposed to PSS or sham-PSS for 15 min. Behaviors were assessed with the elevated plus-maze (EPM) and acoustic startle response (ASR) paradigms 7 days later. Localized brain expression of Iba-1 was assessed, visualized, and classified based on their morphology and stereological counted. Hydrocortisone and RU486 were administered systemically 10 min post PSS exposure and behavioral responses were measured on day 7 and hippocampal expression of Ionized calcium-binding adaptor molecule 1 (Iba-1) was subsequently evaluated. Animals whose behavior was extremely disrupted (PTSD-phenotype) selectively displayed excessive expression of Iba-1 with concomitant downregulation in the expression of CX3C chemokine receptor 1 (CX3CR1) in hippocampal structures as compared with rats whose behavior was minimally or partially disrupted. Changes in microglial morphology have also been related only to the PTSD-phenotype group. These data indicate that PSS-induced microglia activation in the hippocampus serves as a critical mechanistic link between the HPA-axis and PSS-induced impairment in behavioral responses.
Identifiants
pubmed: 35806185
pii: ijms23137185
doi: 10.3390/ijms23137185
pmc: PMC9266429
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Israel Academy of Science and Humanities
ID : 1180/20
Références
Neuroscience. 2007 May 25;146(3):1388-99
pubmed: 17433555
J Neurosci Methods. 2006 Mar 15;151(2):121-30
pubmed: 16125247
Eur Neuropsychopharmacol. 2014 Dec;24(12):1925-44
pubmed: 25451698
Arch Gen Psychiatry. 1991 Mar;48(3):216-22
pubmed: 1996917
Nat Neurosci. 2010 Apr;13(4):411-3
pubmed: 20305648
PLoS One. 2013 Oct 09;8(10):e76146
pubmed: 24130763
Endocr Rev. 2000 Feb;21(1):55-89
pubmed: 10696570
Int J Neuropsychopharmacol. 2008 May;11(3):331-49
pubmed: 17655807
J Neuroinflammation. 2014 Feb 03;11:26
pubmed: 24490760
Mol Pain. 2016 Nov 15;12:
pubmed: 27852966
Physiol Behav. 1993 Dec;54(6):1109-11
pubmed: 8295949
Cereb Cortex. 2013 Aug;23(8):1784-97
pubmed: 22710611
J Neurosci. 2011 Nov 9;31(45):16241-50
pubmed: 22072675
Science. 2011 Sep 9;333(6048):1456-8
pubmed: 21778362
Ann N Y Acad Sci. 2004 Dec;1032:167-78
pubmed: 15677404
Cereb Cortex. 2012 Jun;22(6):1442-54
pubmed: 21878486
Neuropsychopharmacology. 2012 Oct;37(11):2388-404
pubmed: 22713910
Lancet Psychiatry. 2015 Nov;2(11):1002-12
pubmed: 26544749
J Cereb Blood Flow Metab. 2015 Oct;35(10):1623-31
pubmed: 25966946
Int J Neuropsychopharmacol. 2007 Dec;10(6):741-58
pubmed: 17291374
Neurosci Biobehav Rev. 1997 Nov;21(6):783-9
pubmed: 9415903
Curr Protoc Neurosci. 2013 Jul;Chapter 9:Unit 9.45
pubmed: 23853112
Brain Behav Immun. 2007 Jan;21(1):47-59
pubmed: 16647243
Eur Neuropsychopharmacol. 2009 Nov;19(11):759-71
pubmed: 19464153
Psychoneuroendocrinology. 2012 Sep;37(9):1491-505
pubmed: 22386198
Depress Anxiety. 1999;10(1):8-17
pubmed: 10499184
Nat Rev Neurosci. 2016 Aug;17(8):497-511
pubmed: 27277867
Cell. 2013 Dec 19;155(7):1596-609
pubmed: 24360280
Physiol Behav. 1998 Feb 15;63(4):561-9
pubmed: 9523899
Physiol Behav. 1993 Jul;54(1):101-9
pubmed: 8327588
Biol Psychiatry. 2008 Oct 15;64(8):708-717
pubmed: 18635156
Neuropsychopharmacology. 2011 Oct;36(11):2286-302
pubmed: 21734649
Arch Gen Psychiatry. 1998 Jul;55(7):626-32
pubmed: 9672053
Exp Neurol. 2016 Oct;284(Pt B):133-140
pubmed: 27481726
Neuropsychopharmacology. 2004 Nov;29(11):1962-70
pubmed: 15257304
Proc Natl Acad Sci U S A. 2010 May 18;107(20):9470-5
pubmed: 20439746
Psychoneuroendocrinology. 2011 Jun;36(5):720-7
pubmed: 21093988
Behav Neurosci. 2011 Aug;125(4):632-8
pubmed: 21688892
Biol Psychiatry. 1998 Dec 15;44(12):1305-13
pubmed: 9861473
Brain Behav Immun. 2013 Oct;33:1-6
pubmed: 23459026
Eur Neuropsychopharmacol. 2010 Apr;20(4):253-71
pubmed: 20129764
Psychoneuroendocrinology. 2012 Nov;37(11):1822-36
pubmed: 22503138
Clin Exp Neuroimmunol. 2016 May;7(2):114-125
pubmed: 27840659
J Neuroimmunol. 2006 Feb;171(1-2):72-85
pubmed: 16278020
Am J Pathol. 2010 Nov;177(5):2549-62
pubmed: 20864679
Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):13529-34
pubmed: 25114262
Brain Behav Immun. 2013 Feb;28:196-206
pubmed: 23207108
Nat Neurosci. 2006 Jul;9(7):917-24
pubmed: 16732273
Dev Neurobiol. 2021 Jul;81(5):568-590
pubmed: 33583110
J Neuroimmunol. 2011 Apr;233(1-2):29-36
pubmed: 21115202
Brain Behav Immun. 2013 Mar;29:136-146
pubmed: 23305936
Dis Markers. 2011;30(2-3):123-32
pubmed: 21508516
Curr Drug Targets. 2013 Oct;14(11):1262-76
pubmed: 24020974
J Neurotrauma. 2019 Jan 15;36(2):380-394
pubmed: 29947272
Mol Neurobiol. 2014 Jun;49(3):1422-34
pubmed: 24395130
Eur Neuropsychopharmacol. 2000 Dec;10(6):429-35
pubmed: 11115731
Am J Med Genet B Neuropsychiatr Genet. 2011 Sep;156B(6):700-8
pubmed: 21714072
Trends Neurosci. 2007 Nov;30(11):596-602
pubmed: 17950926
Biol Psychiatry. 2003 Mar 15;53(6):463-73
pubmed: 12644351
Biol Psychiatry. 2006 Oct 1;60(7):767-76
pubmed: 16735032
Biol Psychiatry. 2005 Oct 15;58(8):640-50
pubmed: 15978551
J Neuroinflammation. 2011 Jan 25;8:9
pubmed: 21266082
Pharmacol Ther. 2013 Sep;139(3):313-26
pubmed: 23644076
Brain Behav Immun. 2018 Mar;69:62-73
pubmed: 29104062
Int J Neuropsychopharmacol. 2007 Apr;10(2):203-9
pubmed: 16674834
Brain Behav Immun. 2002 Aug;16(4):461-76
pubmed: 12096891
Brain Behav Immun. 2011 Mar;25(3):524-31
pubmed: 21145962
Brain Behav Immun. 2012 Feb;26(2):337-45
pubmed: 22041296
Front Neuroendocrinol. 2004 Jul;25(2):69-76
pubmed: 15571755
Eur Neuropsychopharmacol. 2015 Jan;25(1):124-32
pubmed: 25487770
Neuropsychopharmacology. 2012 Jan;37(2):350-63
pubmed: 21976046
J Neurosci. 1985 May;5(5):1228-32
pubmed: 3998819
J Neurobiol. 2006 May;66(6):552-63
pubmed: 16555237
Biol Psychiatry. 2006 Jun 15;59(12):1208-18
pubmed: 16458266
Physiol Behav. 2013 Oct 2;122:246-52
pubmed: 23707717
Brain Res Bull. 2012 Aug 1;88(5):471-6
pubmed: 22537595
Nat Neurosci. 2015 Oct;18(10):1386-93
pubmed: 26404713
Depress Anxiety. 1996-1997;4(3):144-5
pubmed: 9166644
J Neurosci. 2011 Apr 27;31(17):6277-88
pubmed: 21525267
Brain Behav Immun. 2010 Oct;24(7):1058-68
pubmed: 20153418
Neurosci Biobehav Rev. 1997 Nov;21(6):755-65
pubmed: 9415900
J Neuroinflammation. 2012 Apr 20;9:71
pubmed: 22520439
Neurosci Biobehav Rev. 1990 Winter;14(4):463-72
pubmed: 2287483
Behav Brain Res. 2016 Jul 15;308:128-42
pubmed: 27105958
Psychopharmacology (Berl). 2016 May;233(9):1637-50
pubmed: 26847047
Neuropharmacology. 2012 Feb;62(2):715-24
pubmed: 21565209
ILAR J. 2014;55(2):233-45
pubmed: 25225303
Dis Markers. 2011;30(2-3):141-50
pubmed: 21508518